Department of Blood Purification, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Ther Apher Dial. 2022 Apr;26(2):267-274. doi: 10.1111/1744-9987.13729. Epub 2021 Sep 13.
The aim of this study was to delve into whether beta-2 microglobulin could assess all-cause mortality in patients with chronic kidney disease. PubMed and Embase were systematically searched. Hazard risk and 95% CI were pooled using random-effect models. A total of eight studies were involved according to the inclusion and exclusion criterions. By meta-analysis, each 1 mg/L increase in beta-2 microglobulin displayed positive relationships to the risk of all-cause mortality (hazard risk 1.03, 95% CI = 1.02-1.03) and cardiovascular events (hazard risk 1.04, 95% CI = 1.00-1.08) in patients with dialysis. However, the relationship between elevated level of serum beta-2 microglobulin as a categorical variable and mortality was not significant. The prognostic value of elevated beta-2 microglobulin might be significant in ESRD patients with dialysis and a proper cutoff value to predict mortality should be determined in the future.
本研究旨在深入探讨β-2 微球蛋白是否可用于评估慢性肾脏病患者的全因死亡率。通过系统检索 PubMed 和 Embase 数据库，采用随机效应模型对风险比（HR）及其 95%置信区间（CI）进行合并。根据纳入和排除标准，共有 8 项研究符合要求。荟萃分析显示，β-2 微球蛋白每增加 1mg/L，透析患者全因死亡率（HR=1.03，95%CI=1.02-1.03）和心血管事件风险（HR=1.04，95%CI=1.00-1.08）均呈正相关。然而，血清β-2 微球蛋白水平升高作为分类变量与死亡率之间的关系并无统计学意义。β-2 微球蛋白升高的预后价值可能在接受透析的终末期肾病患者中具有重要意义，未来需要确定合适的截断值来预测死亡率。
